Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Predictive Oncology’s SEC disclosures can feel like running a clinical trial of your own—hundreds of pages on AI-driven drug screens, biobank valuations, and FDA-regulated devices. Whether you’re tracking STREAMWAY revenue or the PEDAL platform’s impact on R&D spend, the details hide deep inside 10-K footnotes and 8-K exhibits.
Stock Titan solves that problem. Our AI-powered summaries translate each Predictive Oncology annual report 10-K simplified, every quarterly earnings report 10-Q filing, and each Predictive Oncology 8-K material events explained into clear, actionable language. Need real-time alerts? We surface Predictive Oncology Form 4 insider transactions in real time, flagging executive stock sales before they hit the news. The platform covers the full spectrum—proxy statement executive compensation tables, registration statements, and even niche S-8 filings—updated the minute EDGAR posts.
Looking for specific answers? Use our search prompts like “understanding Predictive Oncology SEC documents with AI” or “Predictive Oncology earnings report filing analysis” and jump straight to AI-generated highlights: segment revenue trends, cash runway projections, and risk-factor changes. Monitor Predictive Oncology insider trading Form 4 transactions, compare R&D outlays quarter-over-quarter, or download clean tables for your own models. With comprehensive filing coverage, plain-English explanations, and machine-learning insights, Stock Titan turns complex biotech disclosures into practical intelligence investors actually use.
Predictive Oncology Inc. filed a prospectus supplement to its existing S-3 ATM program, updating the amount it may sell under General Instruction I.B.6. As of October 29, 2025, the company may offer and sell common stock with an aggregate offering price of up to $18,330,000 through H.C. Wainwright & Co. as sales agent.
The filing notes the I.B.6 framework, allowing primary offerings up to one-third of public float and removal of this limit if public float exceeds $75.0 million. It also states that approximately $2,417,337 of securities were sold under I.B.6 during the prior 12 months.
Predictive Oncology (POAI) filed a prospectus supplement for an at-the-market offering of up to $18,330,000 of common stock under its agreement with H.C. Wainwright, subject to General Instruction I.B.6 limits.
Over the last 12 months, the company sold 139,680 shares for aggregate gross proceeds of approximately $1,872,333 through the ATM. As calculated within 60 days of this supplement, public float was $62,257,699, based on 3,458,934 non‑affiliate shares at $17.9991. The company noted $2,417,337 of securities sold pursuant to I.B.6 in the same period. If public float rises above $75.0 million, the I.B.6 cap would no longer apply; additional capacity would be reflected in a future supplement.
As of October 28, 2025, the company held approximately 5.49 billion Aethir tokens valued at about $159.2 million based on a $0.0290 price.
Predictive Oncology Inc. (POAI) set its Annual Meeting for November 25, 2025 to vote on key items including board elections, auditor ratification, equity plan changes, and a large share issuance tied to pre-funded warrants. Stockholders of record as of October 24, 2025 (3,501,430 shares outstanding) may vote.
The ballot seeks: (1) election of two Class I directors; (2) ratification of KPMG as independent auditor for fiscal 2025; (3) an amendment to the 2024 Equity Incentive Plan to lift the reserve from 66,667 to 1,066,667 shares and cap incentive stock options at 500,000; (4) approval, under Nasdaq Listing Rule 5635(a), of the issuance of 14,903,393 shares of common stock upon exercise of pre-funded warrants to purchase an equal number of shares; and (5) a non-binding say‑on‑pay vote.
The company notes an overhang of 1.5% as of October 13, 2025, which would rise to approximately 24% if the plan amendment to 1,066,667 shares is approved, before any additional shares from pre-funded warrant exercises. A quorum requires 1,167,144 shares present or represented by proxy.
Predictive Oncology Inc. filed a resale registration covering up to 5,970,181 shares of common stock, to be sold from time to time by the selling stockholders after effectiveness. The company is not offering any shares.
The registered amount includes 3,365,690 PIPE Shares issued in August and September private placements, plus 2,604,491 shares issuable upon warrant exercise, consisting of 1,037,250 Cash PIPE Warrant Shares, 218,335 Agent Warrant Shares, and 1,348,906 Advisor Warrant Shares.
No proceeds will go to the company from stockholder resales. The company would receive cash only upon warrant exercises. The Cash PIPE Warrants carry a nominal $0.01 per-share exercise price; Agent and Advisor Warrants are exercisable at $11.6265 per share. POAI trades on Nasdaq; the last reported price was $9.30 per share on October 21, 2025.
Predictive Oncology Inc. filed a resale registration covering up to 14,903,393 shares of common stock underlying pre-funded warrants issued under a September 29, 2025 securities purchase agreement. The shares may be sold from time to time by the selling stockholders named in the prospectus.
The company is not offering any shares and will not receive proceeds from sales by the selling stockholders; it would receive only any cash paid upon warrant exercise. The warrants carry a $0.01 per share exercise price, have no expiration, and include a 19.99% beneficial ownership limitation. Exercise of these warrants is subject to shareholder approval for the underlying share issuance.
As context, the company’s Nasdaq ticker is POAI, and the last reported sale price was $9.30 per share on October 21, 2025. The filing notes a recent 1-for-15 reverse stock split effective September 30, 2025, and outlines a separate cash PIPE and a crypto-funded PIPE that introduced these pre-funded warrants. The plan of distribution permits various sale methods by the selling holders.
Predictive Oncology Inc. (POAI) filed a Form 3 for a director, the initial statement of beneficial ownership under Section 16. The filing states no securities are beneficially owned as of the event date 10/07/2025. The submission includes an Exhibit 24.1 Power of Attorney, and was signed by Josh Blacher, Attorney-in-Fact. This is an administrative disclosure and does not reflect a transaction.
Predictive Oncology (POAI)no securities are beneficially owned as of the event date 10/08/2025.
The filing includes Exhibit 24.1, a Power of Attorney, and was submitted as a single‑person filing.
Predictive Oncology set its 2025 annual meeting for November 25, 2025, in Pittsburgh at DLA Piper LLP (US). Stockholders of record on October 24, 2025 will be entitled to vote.
Stockholder proposals and proxy access requests must be received by October 26, 2025. The company expects to mail definitive proxy materials on or about November 3, 2025 and may supplement those materials, and if necessary postpone the meeting, to address any timely proposals.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
